RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
RT @medicosergio: Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Ma…
Que rápido vamos, no? Siempre en beneficio de los pacientes Control farmacológico de la glucosa en DMT2 - #Diabetes 👉 Manejo del control de peso, actividad física y metformina como 1ra línea, observé el siguiente escalón terapéutico con base en ECV y ERC
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @Acmi60: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the Eu…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @Office_j: 【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia…
【雑記】EASDとADAは合同で、2型DM血糖管理に関するコンセンサスレポートを公表。2015年版を改訂。薬剤治療の第一選択はメトホルミンで変更なし。併用薬はCV疾患合併例ではSGLT2阻害薬とGLP-1アナログを推奨。 Diabetologia https://t.co/MG739ryDuo https://t.co/d0RcAUGMvk
RT @Acmi60: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the Eu…
RT @Acmi60: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the Eu…
RT @Acmi60: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the Eu…
RT @Diabetes_SEMI: EASD y ADA publican un un nuevo consenso de hipeglucemias en diabeticos tipo 2 #diabetes https://t.co/3Ept3yW9C0
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @Acmi60: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the Eu…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
New EASD/ADA consensus report on #T2D highlights: 1) focus on lifestyle & diabetes self-management education/support 2) comorbidities (CVD/HF/CKD), hypoglycaemia/weight & patient preference drive choice of therapy @EASDnews @AmDiabetesAssn @uniofle
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
EASD y ADA publican un un nuevo consenso de hipeglucemias en diabeticos tipo 2 #diabetes https://t.co/3Ept3yW9C0
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
Consenso en diabetes tipo 2. Ciencia centrada en el paciente. https://t.co/PfSG30MT1C https://t.co/GGcnYrXTT6
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
Thanks for sharing @chris_magz, I'm sure @parthaskar, & @Paddy_English et al will be interested in this
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
RT @DiabetologiaJnl: EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDne…
EASD and ADA publish new consensus report on #GlucoseLowering and #PatientCentredCare in type 2 diabetes. #T2D @EASDnews @AmDiabetesAssn @profmjdavies @uniofleicester https://t.co/XQtDwfkLqj